Asplenia primary prevention: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Asplenia}} | {{Asplenia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Anum Dilip}} | ||
==Overview== | ==Overview== | ||
Line 45: | Line 45: | ||
{{WS}} | {{WS}} | ||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Primary care]] | |||
[[Category:Immunology]] | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category: | [[Category:Emergency medicine]] |
Revision as of 02:49, 30 June 2020
Asplenia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Asplenia primary prevention On the Web |
American Roentgen Ray Society Images of Asplenia primary prevention |
Risk calculators and risk factors for Asplenia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anum Dilip, M.B.B.S[2]
Overview
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
Primary Prevention
There are no established measures for the primary prevention of [disease name].
OR
There are no available vaccines against [disease name].
OR
Effective measures for the primary prevention of [disease name] include:
- [Measure1]
- [Measure2]
- [Measure3]
OR
[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]